Adlai Nortye (NASDAQ:ANL) is one of the small stocks that are on fire right now. On April 16, Adlai Nortye entered into a securities purchase agreement for a private placement equity financing/PIPE expected to generate gross proceeds of ~$150 million. The oversubscribed transaction saw significant participation from a broad group of new and existing healthcare institutional investors, including Soleus Capital, Perceptive Advisors and Cormorant Asset Management.
The company is selling more than 11.3 million American Depositary Shares/ADS at $13.25 per share, matching its closing price on April 15. The capital injection is intended to advance Adlai Nortye’s clinical stage, specifically its RAS-targeted therapies and its proprietary next-generation ADC (antibody-drug conjugate) payload platform, RASiCA. These technologies are critical to the company’s mission to transform terminal cancers into manageable chronic diseases.
Jirsak/Shutterstock.com
As part of the agreement, Adlai Nortye (NASDAQ:ANL) agreed to file a registration statement with the SEC to permit the resale of the ADSs issued in the placement. High-profile firms including Leerink Partners and Cantor acted as joint bookrunners for the deal, underscoring strong market interest in the company’s specialist oncology platform.
Adlai Nortye (NASDAQ:ANL) is a global clinical-stage company developing innovative cancer therapies through R&D centers in the US and China. Its portfolio includes RAS-targeted therapies, including the pan-RAS(ON) inhibitor AN9025, and next-generation immunotherapies such as the trifunctional fusion protein AN8025 and the oral PD-L1 inhibitor AN4005.
While we recognize ANL’s potential as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 33 stocks that should double in 3 years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.